Amplimune® Now Available in New Zealand
NovaVive's immunotherapy for calf scours - Amplimune® - is now available in the New Zealand market. The product was approved for sale by Agricultural Compounds and Veterinary Medicines (ACVM) last September.
News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
MCWF Greatly Improves Pregnancy Success in Heifer Embryo Transfer Recipients
An abstract being presented at the 2021 IETS Virtual Conference summarizes data from a study showing 45% of Amplimune-treated embryo transfer recipient heifers achieved pregnancy at Day 60 vs. 28% of untreated controls.
Amplimune® Receives Regulatory Approval in New Zealand
NovaVive's immunotherapy for calf scours - Amplimune® - has received approval for sale in New Zealand by Agricultural Compounds and Veterinary Medicines (ACVM). NovaVive has appointed Agilis Vet Ltd as its NZ distributor.
NovaVive Seeking to Enhance Quality of Life of Dogs with Cancer
Immunocidin is being evaluated in a clinical study as a palliative therapy for dogs with malignant cancer. The goal is to increase the dogs' comfort and maintain or improve the quality and duration of their remaining life.
Results from a Study with Immunocidin® Equine for Sarcoid Tumors Being Published in the Journal of Equine Veterinary Science
An Iowa State University study concluded that Immunocidin Equine was effective in 52.9% of the cases enrolled (that had a known outcome) after 2-5 injections. The treatment was deemed safe, with swelling the only side effect.
Positive Effect of Settle® on Postpartum Involution Published in the Journal of Equine Veterinary Science
Data from a study with Settle® has been published in the Journal of Equine Veterinary Science. The data show a positive effect of Settle on postpartum uterine involution in the mare, particularly with a two-dose regimen.